This study is for adults with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers want to see how well new treatments work. The new treatments are either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec). They will compare these to a treatment using elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).

Participants must have multiple myeloma that has come back or not responded to previous treatments. They should also have received an anti-CD38 antibody and lenalidomide before joining the study. The study will not accept people with serious allergies to the study drugs or those who had a stroke or seizure in the last six months.

• The study requires regular visits to check progress.
• Participants cannot be pregnant or breastfeeding during the study and for six months after the last treatment.
• Risks include allergic reactions or other side effects from the drugs.